TY - JOUR
T1 - Nitroimidazoles
T2 - Molecular fireworks that combat a broad spectrum of infectious diseases
AU - Ang, Chee Wei
AU - Jarrad, Angie M.
AU - Cooper, Matthew A.
AU - Blaskovich, Mark A.T.
N1 - Funding Information:
C.W.A. is supported by an Australian Government Research Training Program (RTP) Scholarship. A.M.J. was supported by an Australian Postgraduate Award PhD Scholarship, Queensland Government Smart Futures Scholarship and IMB Postgraduate Scholarship. M.A.C. is supported in part by an NHMRC Principal Research Fellowship (APP1059354). M.A.T.B. is supported in part by Wellcome Trust Strategic Grant WT1104797/Z/14/Z.
Publisher Copyright:
© 2017 American Chemical Society.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2017/9/28
Y1 - 2017/9/28
N2 - Infectious diseases claim millions of lives every year, but with the advent of drug resistance, therapeutic options to treat infections are inadequate. There is now an urgent need to develop new and effective treatments. Nitroimidazoles are a class of antimicrobial drugs that have remarkable broad spectrum activity against parasites, mycobacteria, and anaerobic Gram-positive and Gram-negative bacteria. While nitroimidazoles were discovered in the 1950s, there has been renewed interest in their therapeutic potential, particularly for the treatment of parasitic infections and tuberculosis. In this review, we summarize different classes of nitroimidazoles that have been described in the literature in the past five years, from approved drugs and clinical candidates to examples undergoing preclinical or early stage development. The relatively "nonspecific" mode of action and resistance mechanisms of nitromidazoles are discussed, and contemporary strategies to facilitate nitroimidazole drug development are highlighted.
AB - Infectious diseases claim millions of lives every year, but with the advent of drug resistance, therapeutic options to treat infections are inadequate. There is now an urgent need to develop new and effective treatments. Nitroimidazoles are a class of antimicrobial drugs that have remarkable broad spectrum activity against parasites, mycobacteria, and anaerobic Gram-positive and Gram-negative bacteria. While nitroimidazoles were discovered in the 1950s, there has been renewed interest in their therapeutic potential, particularly for the treatment of parasitic infections and tuberculosis. In this review, we summarize different classes of nitroimidazoles that have been described in the literature in the past five years, from approved drugs and clinical candidates to examples undergoing preclinical or early stage development. The relatively "nonspecific" mode of action and resistance mechanisms of nitromidazoles are discussed, and contemporary strategies to facilitate nitroimidazole drug development are highlighted.
UR - http://www.scopus.com/inward/record.url?scp=85030216232&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.7b00143
DO - 10.1021/acs.jmedchem.7b00143
M3 - Review Article
C2 - 28463485
AN - SCOPUS:85030216232
SN - 0022-2623
VL - 60
SP - 7636
EP - 7657
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 18
ER -